Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.